HER2-Positive Breast Cancer Treatment in Shanghai – A Guide for International Patients | CMCS

HER2-Positive Breast Cancer Treatment in Shanghai: A Guide for International Patients

HER2-positive breast cancer — defined by overexpression or amplification of the HER2 (human epidermal growth factor receptor 2) protein — accounts for approximately 15–20% of all breast cancers. Once considered one of the most aggressive subtypes, HER2-positive breast cancer has been transformed by targeted therapy into one of the most treatable. The development of trastuzumab (Herceptin) in the late 1990s was a landmark moment in oncology, and the subsequent generation of HER2-targeted agents has continued to improve outcomes dramatically.

For international patients, Shanghai offers access to the full spectrum of HER2-targeted therapies — including newer agents such as trastuzumab deruxtecan (T-DXd / Enhertu) and tucatinib — combined with the clinical expertise of China's leading breast oncology centers. This guide explains the current treatment landscape, which specialists and institutions to consider, and how CMCS can coordinate your care.

Understanding HER2-Positive Breast Cancer

HER2 Testing: HER2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). HER2-positive is defined as IHC 3+ or IHC 2+ with FISH amplification confirmed. A new category — HER2-low (IHC 1+ or IHC 2+/FISH-negative) — has emerged as clinically significant with the approval of T-DXd in this population. If your HER2 status is borderline or was tested some time ago, re-testing on current tissue is recommended.

Hormone Receptor Co-expression: HER2-positive tumors may also be hormone receptor-positive (HR+/HER2+) or hormone receptor-negative (HR-/HER2+). This distinction affects treatment sequencing, as HR+/HER2+ patients may benefit from endocrine therapy in addition to HER2-targeted agents.

Brain Metastases: HER2-positive breast cancer has a higher propensity for brain metastasis than other subtypes. Approximately 30–50% of patients with metastatic HER2-positive disease will develop brain metastases during their illness. This makes CNS-penetrant HER2-targeted agents (tucatinib, neratinib, T-DXd) particularly important in the metastatic setting.

HER2-Low Breast Cancer: A New Category

The approval of trastuzumab deruxtecan (T-DXd / Enhertu) for HER2-low metastatic breast cancer — based on the DESTINY-Breast04 trial — has redefined how pathologists and oncologists classify HER2 expression. Patients previously considered HER2-negative (IHC 1+ or IHC 2+/FISH-) are now recognized as a distinct population eligible for T-DXd. If you have been told your tumor is HER2-negative, it is worth confirming whether your IHC score was 1+ or 2+, as this may affect treatment eligibility.

Treatment by Disease Stage

Early-Stage HER2-Positive Breast Cancer (Stages I–III)

Neoadjuvant chemotherapy + dual HER2 blockade: The standard approach for most early-stage HER2-positive patients is neoadjuvant (pre-surgical) chemotherapy combined with trastuzumab and pertuzumab (dual HER2 blockade). The NEOSPHERE and TRYPHAENA trials established this as the standard of care, with pathological complete response (pCR) rates of 40–60% in HER2-positive/HR-negative tumors.

Surgery: Breast-conserving surgery or mastectomy based on tumor size, location, and patient preference, with sentinel lymph node biopsy or axillary dissection as indicated.

Adjuvant therapy based on pCR status:

• pCR achieved: Continue trastuzumab (with or without pertuzumab) to complete one year of HER2-targeted therapy. For HR+ patients, endocrine therapy is added.
• Residual disease (non-pCR): Switch to adjuvant T-DM1 (ado-trastuzumab emtansine / Kadcyla) for 14 cycles, based on the KATHERINE trial, which demonstrated a 50% reduction in recurrence risk versus trastuzumab alone.

Extended adjuvant neratinib: For HR+/HER2+ patients who have completed one year of trastuzumab-based therapy, one year of adjuvant neratinib (an irreversible pan-HER tyrosine kinase inhibitor) further reduces recurrence risk, particularly for brain metastases.

Metastatic HER2-Positive Breast Cancer (Stage IV)

The metastatic HER2-positive treatment landscape has been transformed by a succession of highly active agents:

First-line: Trastuzumab + pertuzumab + taxane (CLEOPATRA regimen): The CLEOPATRA trial established this triplet as the standard first-line regimen for metastatic HER2-positive breast cancer, with median overall survival exceeding 57 months — a remarkable outcome for metastatic breast cancer.

Second-line: Trastuzumab deruxtecan (T-DXd / Enhertu): The DESTINY-Breast03 trial demonstrated that T-DXd is superior to T-DM1 as second-line therapy for HER2-positive metastatic breast cancer, with a hazard ratio for progression of 0.28 — one of the most dramatic results in breast oncology history. T-DXd has become the preferred second-line standard of care globally and is available in Shanghai.

Third-line and beyond: Tucatinib + trastuzumab + capecitabine (HER2CLIMB regimen): Particularly important for patients with brain metastases, as tucatinib penetrates the CNS. The HER2CLIMB trial showed significant improvement in overall survival including in patients with active brain metastases.

T-DM1 (Kadcyla): Remains an option in later lines for patients who have not previously received it.

Lapatinib-based combinations: Lapatinib + capecitabine or lapatinib + trastuzumab are later-line options with established activity.

Clinical trials: Novel HER2-targeted ADCs, bispecific antibodies, and combination strategies are in active development. Shanghai's leading centers have access to early-phase and registration trials for HER2-positive breast cancer.

Brain Metastases in HER2-Positive Breast Cancer

Brain metastases require a specialized multidisciplinary approach combining systemic HER2-targeted therapy with local brain-directed treatment. Options include:

• Stereotactic radiosurgery (SRS) for limited brain metastases — available at leading Shanghai centers
• Whole brain radiation therapy (WBRT) for extensive brain involvement
• CNS-penetrant systemic agents (tucatinib, neratinib, T-DXd) to treat both intracranial and extracranial disease simultaneously
• Neurosurgical resection for large or symptomatic single metastases

CMCS coordinates across neurosurgery, radiation oncology, and medical oncology teams to ensure integrated management of brain metastases in HER2-positive patients.

Leading Shanghai Specialists for HER2-Positive Breast Cancer

Fudan University Shanghai Cancer Center (FUSCC)

FUSCC is China's national leader in breast cancer and has been at the forefront of HER2-targeted therapy research and implementation. Its medical oncology faculty have led or participated in landmark HER2-positive breast cancer trials and have extensive experience managing complex metastatic cases including brain metastases.

CMCS works with leading FUSCC breast oncologists including:

• Prof. Zhang Jian (张剑) — medical oncologist with deep expertise in HER2-positive breast cancer systemic therapy
• Prof. Wang Biyun (王碧詠) — expert in metastatic breast cancer including HER2-positive disease
• Dr. Wang Jialei (王佳蔓) — medical oncologist specializing in breast cancer
• Prof. Wu Jiong (吴炵) — Chief of Breast Surgery, expert in surgical management of HER2-positive tumors

Ruijin Hospital — Shanghai Jiao Tong University

Prof. Shen Kunwei (沈坤炮) leads one of Shanghai's most respected breast surgery programs outside of FUSCC, with comprehensive multidisciplinary support for HER2-positive patients.

Huashan Hospital — Fudan University

Dr. Zhuang Rongyuan (庄荣源) provides medical oncology expertise for breast cancer patients including HER2-positive disease within the Fudan University medical network.

What to Prepare Before Your Shanghai Consultation

• Pathology report with HER2 IHC score, FISH result, ER/PR status, Ki-67, and histological grade
• HER2 testing slides or blocks (if re-testing is being considered)
• Staging imaging: CT chest/abdomen/pelvis, bone scan or PET-CT
• Brain MRI (with and without contrast) — particularly important for metastatic HER2-positive patients
• Prior treatment records: all HER2-targeted agents received, chemotherapy regimens, response assessments
• Cardiac function assessment: echocardiogram or MUGA scan (HER2-targeted agents require cardiac monitoring)
• Surgical records if prior surgery has been performed
• Radiation treatment summary if applicable

How CMCS Coordinates HER2-Positive Breast Cancer Care in Shanghai

China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For HER2-positive breast cancer patients, our coordination includes:

• Case triage to the most appropriate medical oncologist and surgical team
• Medical record translation and clinical summary preparation
• Multidisciplinary tumor board submission and review coordination
• Appointment scheduling across medical oncology, breast surgery, radiation oncology, and neurosurgery (for brain metastases)
• On-site interpretation during all consultations and procedures
• Clinical trial eligibility assessment and enrollment support
• Cardiac monitoring coordination during HER2-targeted therapy
• Post-treatment follow-up and surveillance coordination
• Liaison with the patient's home oncologist for continuity of care

Contact CMCS to Begin Your Consultation

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com

CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.